Liberty Francois-Moutal - Publications

Affiliations: 
2014-2021 Pharmacology University of Arizona, Tucson, AZ 

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 François-Moutal L, Scott DD, Ambrose AJ, Zerio CJ, Rodriguez-Sanchez M, Dissanayake K, May DG, Carlson JM, Barbieri E, Moutal A, Roux KJ, Shorter J, Khanna R, Barmada SJ, McGurk L, et al. Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology. Scientific Reports. 12: 8140. PMID 35581326 DOI: 10.1038/s41598-022-12191-8  0.504
2022 Mollasalehi N, Francois-Moutal L, Porciani D, Burke DH, Khanna M. Aptamers Targeting Hallmark Proteins of Neurodegeneration. Nucleic Acid Therapeutics. PMID 35452303 DOI: 10.1089/nat.2021.0091  0.765
2021 Cai S, Moutal A, Yu J, Chew LA, Isensee J, Chawla R, Gomez K, Luo S, Zhou Y, Chefdeville A, Madura C, Perez-Miller S, Bellampalli SS, Dorame A, Scott DD, et al. Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Science Translational Medicine. 13: eabh1314. PMID 34757807 DOI: 10.1126/scitranslmed.abh1314  0.688
2021 Francois-Moutal L, Scott DD, Khanna M. Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape. Rsc Chemical Biology. 2: 1158-1166. PMID 34458829 DOI: 10.1039/d1cb00110h  0.721
2021 François-Moutal L, Miranda VG, Mollasalehi N, Gokhale V, Khanna M. Targeting of the Long Noncoding RNA MALAT1. Acs Medicinal Chemistry Letters. 12: 915-921. PMID 34141069 DOI: 10.1021/acsmedchemlett.1c00060  0.763
2020 Mollasalehi N, Francois-Moutal L, Scott DD, Tello JA, Williams H, Mahoney B, Carlson JM, Dong Y, Li X, Miranda VG, Gokhale V, Wang W, Barmada SJ, Khanna M. An Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 Yields Neuroprotective Properties. Acs Chemical Biology. PMID 33044808 DOI: 10.1021/acschembio.0c00494  0.756
2020 François-Moutal L, Perez-Miller S, Scott DD, Miranda VG, Mollasalehi N, Khanna M. Corrigendum: Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Frontiers in Molecular Neuroscience. 13: 45. PMID 32300293 DOI: 10.3389/Fnmol.2020.00045  0.708
2019 François-Moutal L, Perez-Miller S, Scott DD, Miranda VG, Mollasalehi N, Khanna M. Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Frontiers in Molecular Neuroscience. 12: 301. PMID 31920533 DOI: 10.3389/Fnmol.2019.00301  0.747
2019 Zhou Y, Cai S, Moutal A, Yu J, Gomez K, Madura CL, Shan Z, Ngan Pham NY, Serafini MJ, Dorame A, Scott DD, Francois-Moutal L, Perez-Miller S, Patek M, Khanna M, et al. The natural flavonoid Naringenin elicits analgesia through inhibition of NaV1.8 voltage-gated sodium channels. Acs Chemical Neuroscience. PMID 31697467 DOI: 10.1021/Acschemneuro.9B00547  0.683
2019 Moutal A, Shan Z, Miranda VG, François-Moutal L, Madura CL, Khanna M, Khanna R. Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief. Channels (Austin, Tex.). 13: 498-504. PMID 31680630 DOI: 10.1080/19336950.2019.1684608  0.666
2019 Francois-Moutal L, Scott DD, Felemban R, Miranda VG, Sayegh MR, Perez-Miller S, Khanna R, Gokhale V, Zarnescu DC, Khanna M. A small molecule targeting TDP-43's RNA recognition motifs reduces locomotor defects in a Drosophila model of ALS. Acs Chemical Biology. PMID 31241884 DOI: 10.1021/Acschembio.9B00481  0.748
2019 Khanna R, Yu J, Yang X, Moutal A, Chefdeville A, Gokhale V, Shuja Z, Chew LA, Bellampalli SS, Luo S, François-Moutal L, Serafini MJ, Ha T, Perez-Miller S, Park KD, et al. Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. Pain. PMID 30933958 DOI: 10.1097/J.Pain.0000000000001524  0.677
2019 Scott DD, Francois-Moutal L, Kumirov VK, Khanna M. H, N and C backbone assignment of apo TDP-43 RNA recognition motifs. Biomolecular Nmr Assignments. PMID 30694439 DOI: 10.1007/S12104-018-09870-X  0.751
2018 Francois-Moutal L, Jahanbakhsh S, Nelson A, Ray D, Scott DD, Hennefarth M, Moutal A, Perez-Miller S, Ambrose AJ, Al-Shamari A, Coursodon P, Meechoovet B, Reiman R, Lyons E, Beilstein M, et al. A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B). Acs Chemical Biology. PMID 30141626 DOI: 10.1021/Acschembio.8B00745  0.742
2018 François-Moutal L, Scott DD, Perez-Miller S, Gokhale V, Khanna M, Khanna R. Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. Channels (Austin, Tex.). 1-9. PMID 30081699 DOI: 10.1080/19336950.2018.1491244  0.706
2018 François-Moutal L, Dustrude ET, Wang Y, Brustovetsky T, Dorame A, Ju W, Moutal A, Perez-Miller S, Brustovetsky N, Gokhale V, Khanna M, Khanna R. Inhibition of the Ubc9 E2 SUMO conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain. PMID 29847471 DOI: 10.1097/J.Pain.0000000000001294  0.671
2018 Scott D, Kumirov V, Francois-Moutal L, Khanna M. 1H, 15N and 13C backbone assignment of apoTDP-43 RNA Recognition Motifs Journal of Back and Musculoskeletal Rehabilitation. DOI: 10.13018/Bmr27613  0.644
2017 Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, et al. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain. PMID 28809766 DOI: 10.1097/J.Pain.0000000000001002  0.656
2017 Dustrude ET, Perez-Miller S, François-Moutal L, Moutal A, Khanna M, Khanna R. A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels (Austin, Tex.). 0. PMID 28277940 DOI: 10.1080/19336950.2017.1299838  0.64
2017 Moutal A, Li W, Wang Y, Ju W, Luo S, Cai S, François-Moutal L, Perez-Miller S, Hu J, Dustrude ET, Vanderah TW, Gokhale V, Khanna M, Khanna R. Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of CRMP2-derived peptides. British Journal of Pharmacology. PMID 28161890 DOI: 10.1111/Bph.13737  0.656
2015 Moutal A, François-Moutal L, Perez-Miller S, Cottier K, Chew LA, Yeon SK, Dai J, Park KD, Khanna M, Khanna R. (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. Molecular Neurobiology. PMID 25846820 DOI: 10.1007/S12035-015-9141-2  0.637
2015 François-Moutal L, Wang Y, Moutal A, Cottier KE, Melemedjian OK, Yang X, Wang Y, Ju W, Largent-Milnes TM, Khanna M, Vanderah TW, Khanna R. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain. 156: 1247-64. PMID 25782368 DOI: 10.1097/j.pain.0000000000000147  0.648
2014 Moutal A, François-Moutal L, Brittain JM, Khanna M, Khanna R. Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. Frontiers in Cellular Neuroscience. 8: 471. PMID 25674050 DOI: 10.3389/Fncel.2014.00471  0.619
2014 Wilson SM, Moutal A, Melemedjian OK, Wang Y, Ju W, François-Moutal L, Khanna M, Khanna R. The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. Frontiers in Cellular Neuroscience. 8: 196. PMID 25104922 DOI: 10.3389/Fncel.2014.00196  0.638
Show low-probability matches.